BridgeMD
Development of an optimized dosing regimen of ceftazidime-avibactam in critically ill patients treated with continuous renal replacement therapy
EU CTIS ID: 2023-505536-35-00
What this study is testing
Document exposure and pharmacokinetics of ceftazidime-avibactam in critically ill patients with CRRT
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior – or within 72 hours after oral consent - to the initation of any study-specific procedures.
- Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
- Admission to the ICU ward
- Aged 18 years or older
- Receiving concomitant treatment with ceftazidime-avibactam and any form of continuous renal replacement therapy
You likely can't join if
- Participant has a history of allergic reactions to either ceftazidime or avibactam
- Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol
- Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial
- Female who is pregnant or breast-feeding
- No concomitant ceftazidime-avibactam and CRRT on day of inclusion
- Receiving palliative treatment
See the full eligibility criteria
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior – or within 72 hours after oral consent - to the initation of any study-specific procedures.
- Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.
- Admission to the ICU ward
- Aged 18 years or older
- Receiving concomitant treatment with ceftazidime-avibactam and any form of continuous renal replacement therapy
- Participant has a history of allergic reactions to either ceftazidime or avibactam
- Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol
- Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial
- Female who is pregnant or breast-feeding
- No concomitant ceftazidime-avibactam and CRRT on day of inclusion
- Receiving palliative treatment
- Previous enrolment in this study.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.